CC
MCID: CHL065
MIFTS: 65

Cholangiocarcinoma (CC)

Categories: Cancer diseases, Liver diseases, Rare diseases

Aliases & Classifications for Cholangiocarcinoma

MalaCards integrated aliases for Cholangiocarcinoma:

Name: Cholangiocarcinoma 58 39 77 26 60 38 56 17 74
Cholangiocarcinoma, Susceptibility to 58 30
Intrahepatic Cholangiocarcinoma 26 74
Extrahepatic Cholangiocarcinoma 26 74
Adult Primary Cholangiocellular Carcinoma 74
Cholangiocarcinoma of Biliary Tract 26
Cholangiocellular Carcinoma 26
Chlc, Susceptibility to 58
Bile Duct Carcinoma 74
Bile Duct Cancer 60
Chlc 58
Cca 60
Cc 26

Characteristics:

Orphanet epidemiological data:

60
cholangiocarcinoma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Europe); Age of onset: Adult;

Classifications:

Orphanet: 60  
Rare hepatic diseases


External Ids:

OMIM 58 615619
KEGG 38 H00046
MESH via Orphanet 46 D001650 D018281
ICD10 via Orphanet 35 C22.1 C24.0 C24.8 more
UMLS via Orphanet 75 C0206698 C0740277
Orphanet 60 ORPHA70567
MedGen 43 C3810156

Summaries for Cholangiocarcinoma

OMIM : 58 Carcinomas of the biliary tract are aggressive malignancies, with 5-year survival of less than 10%. These carcinomas arise throughout the biliary tree and are anatomically classified as either intrahepatic or extrahepatic cholangiocarcinomas. Gallbladder carcinomas also arise from the biliary tree but have distinct natural histories compared to cholangiocarcinomas, suggesting different underlying tumor biology. Cholangiocarcinoma incidence varies widely between geographic regions, reflecting the impact of different underlying etiologies. In endemic areas, liver fluke infections by O. viverrini and Clonorchis sinensis, both group I carcinogens, represent the major risk factor for cholangiocarcinomas. In nonendemic regions, other risk factors, including choledochal cysts (603003), hepatolithiasis, and primary sclerosing cholangitis (613806), are likely contributors (summary by Chan-on et al., 2013). Overall, the majority of patients lack such identifiable risk factors (summary by Jiao et al., 2013). (615619)

MalaCards based summary : Cholangiocarcinoma, also known as cholangiocarcinoma, susceptibility to, is related to kidney cancer and gallbladder cancer, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Cholangiocarcinoma is MIR21 (MicroRNA 21), and among its related pathways/superpathways are MicroRNAs in cancer and miRNA targets in ECM and membrane receptors. The drugs Celecoxib and Pancrelipase have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and lung, and related phenotypes are jaundice and biliary tract neoplasm

Genetics Home Reference : 26 Cholangiocarcinoma is a group of cancers that begin in the bile ducts. Bile ducts are branched tubes that connect the liver and gallbladder to the small intestine. They carry bile, which is a fluid that helps the body digest the fats in food. Bile is produced in the liver and stored in the gallbladder before being released in the small intestine after a person eats.

Wikipedia : 77 Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts.... more...

Related Diseases for Cholangiocarcinoma

Diseases related to Cholangiocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 551)
# Related Disease Score Top Affiliating Genes
1 kidney cancer 30.5 H19 MIR141 MIR200B MIR21
2 gallbladder cancer 30.4 AFAP1-AS1 H19 TUG1 UCA1
3 small cell cancer of the lung 30.3 CCAT2 MIR21 TUG1
4 laryngeal squamous cell carcinoma 30.2 H19 MIR21 NEAT1
5 pancreatic ductal adenocarcinoma 30.0 AFAP1-AS1 H19 MIR141 MIR148A MIR21 UCA1
6 glioblastoma 29.9 H19 MIR21 PCAT1 TUG1
7 nasopharyngeal carcinoma 29.8 AFAP1-AS1 H19 HULC NEAT1
8 tongue squamous cell carcinoma 29.8 AFAP1-AS1 MIR21 UCA1
9 myeloma, multiple 29.8 H19 PCAT1 TUG1 UCA1
10 diffuse large b-cell lymphoma 29.7 HULC MIR21 MIR320A PANDAR
11 pancreatic cancer 29.6 AFAP1-AS1 H19 HULC MIR148A MIR21 NEAT1
12 atherosclerosis susceptibility 29.6 H19 HULC TUG1
13 hepatocellular carcinoma 29.6 AFAP1-AS1 CCAT2 H19 HULC MIR141 MIR148A
14 renal cell carcinoma, nonpapillary 29.6 H19 MIR141 PANDAR TUG1 UCA1
15 thyroid cancer 29.6 AFAP1-AS1 H19 NEAT1 PANDAR UCA1
16 squamous cell carcinoma 29.5 CCAT2 H19 NEAT1 PCAT1 SOX2-OT TUG1
17 lung cancer susceptibility 3 29.5 AFAP1-AS1 H19 MIR200B TUG1
18 melanoma 29.4 H19 MIR141 MIR200B MIR204 SOX2-OT UCA1
19 lung squamous cell carcinoma 29.4 CCAT2 SOX2-OT TUG1
20 clear cell renal cell carcinoma 29.4 CCAT2 MIR21 MIR320A PANDAR TUG1
21 leukemia, chronic myeloid 29.3 H19 HULC UCA1
22 cervical cancer 29.3 CCAT2 H19 HULC MIR21 NEAT1 PANDAR
23 leukemia, acute myeloid 29.1 MIR204 MIR21 MIR320A TUG1 UCA1
24 oral squamous cell carcinoma 29.1 CCAT2 H19 MIR200B MIR204 MIR21 NEAT1
25 gastric cancer 28.9 AFAP1-AS1 CCAT2 H19 HULC MIR141 MIR21
26 ovarian cancer 28.9 AFAP1-AS1 CCAT2 H19 MIR141 MIR152 MIR200B
27 bladder cancer 28.9 CCAT2 H19 HULC MIR21 PANDAR PCAT1
28 prostate cancer 28.7 CCAT2 H19 HULC MIR141 MIR148A MIR200B
29 lung cancer 28.7 AFAP1-AS1 CCAT2 H19 MIR141 MIR148A MIR200B
30 osteogenic sarcoma 28.7 CCAT2 H19 HULC NEAT1 PANDAR PCAT1
31 colorectal cancer 28.6 AFAP1-AS1 CCAT2 H19 HULC MIR141 MIR21
32 breast cancer 28.2 CCAT2 H19 MIR141 MIR148A MIR152 MIR200B
33 intrahepatic cholangiocarcinoma 12.7
34 arthrogryposis, distal, type 9 12.3
35 combined hepatocellular carcinoma and cholangiocarcinoma 12.3
36 sarcomatous intrahepatic cholangiocarcinoma 12.3
37 mucinous intrahepatic cholangiocarcinoma 12.3
38 klatskin's tumor 12.2
39 signet ring cell intrahepatic cholangiocarcinoma 12.1
40 epilepsy occipital calcifications 11.6
41 clonorchiasis 11.6
42 bile duct cancer 11.5
43 biliary tract cancer 11.5
44 cholangitis, primary sclerosing 11.5
45 opisthorchiasis 11.4
46 acrocallosal syndrome 11.3
47 central cord syndrome 11.3
48 familial calcium pyrophosphate deposition 11.3
49 cholangitis 10.8
50 sclerosing cholangitis 10.7

Graphical network of the top 20 diseases related to Cholangiocarcinoma:



Diseases related to Cholangiocarcinoma

Symptoms & Phenotypes for Cholangiocarcinoma

Human phenotypes related to Cholangiocarcinoma:

60 33 (show all 9)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 jaundice 60 33 hallmark (90%) Very frequent (99-80%) HP:0000952
2 biliary tract neoplasm 60 33 hallmark (90%) Very frequent (99-80%) HP:0100574
3 acholic stools 60 33 hallmark (90%) Very frequent (99-80%) HP:0011985
4 fatigue 60 33 frequent (33%) Frequent (79-30%) HP:0012378
5 pruritus 60 33 frequent (33%) Frequent (79-30%) HP:0000989
6 fever 60 33 occasional (7.5%) Occasional (29-5%) HP:0001945
7 abdominal pain 60 33 occasional (7.5%) Occasional (29-5%) HP:0002027
8 anorexia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002039
9 cholangiocarcinoma 33 HP:0030153

Clinical features from OMIM:

615619

UMLS symptoms related to Cholangiocarcinoma:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas, malaise

Drugs & Therapeutics for Cholangiocarcinoma

Drugs for Cholangiocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 336)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
2
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 53608-75-6
3
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
4
Desflurane Approved Phase 4,Not Applicable 57041-67-5 42113
5
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 6857599 5310940 9887054 43805
6
Etomidate Approved Phase 4 33125-97-2 36339 667484
7
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
8
Meperidine Approved Phase 4 57-42-1 4058
9
Bilirubin Phase 4,Not Applicable 635-65-4, 69853-43-6 5280352 21252250
10 Antirheumatic Agents Phase 4,Phase 1,Phase 2
11 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Analgesics, Non-Narcotic Phase 4,Phase 1,Phase 2
13 pancreatin Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Analgesics Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
15 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
16 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2
17 Cyclooxygenase Inhibitors Phase 4
18 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 1,Phase 2
19 Cyclooxygenase 2 Inhibitors Phase 4
20 arginine Phase 4
21 Omega 3 Fatty Acid Phase 4
22 Anesthetics, General Phase 4,Phase 3,Not Applicable
23 Platelet Aggregation Inhibitors Phase 4
24 Liver Extracts Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
25 Anesthetics Phase 4,Phase 3,Not Applicable
26 Anesthetics, Inhalation Phase 4,Not Applicable
27 Central Nervous System Depressants Phase 4,Phase 3,Not Applicable
28 Cola Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
29
Bismuth Phase 4,Phase 3 7440-69-9 16682734 105143
30 Hypnotics and Sedatives Phase 4,Not Applicable
31 GABA Agents Phase 4,Not Applicable
32 GABA Modulators Phase 4,Not Applicable
33 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Tranquilizing Agents Phase 4,Phase 3
35 Adjuvants, Anesthesia Phase 4,Phase 3
36 Anti-Anxiety Agents Phase 4,Phase 3
37 Psychotropic Drugs Phase 4,Phase 3
38 Narcotics Phase 4,Phase 3,Not Applicable
39 Anesthetics, Intravenous Phase 4,Phase 3,Not Applicable
40 Analgesics, Opioid Phase 4,Phase 3,Not Applicable
41 Ulipristal acetate Phase 4 126784-99-4
42
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
43
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
44
Trioxsalen Approved Phase 2, Phase 3,Phase 3,Not Applicable 3902-71-4 5585
45
Fluorouracil Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 51-21-8 3385
46
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 6006 143
47
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 68538-85-2
48
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
49
Ursodeoxycholic acid Approved, Investigational Phase 2, Phase 3 128-13-2 31401
50
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345

Interventional clinical trials:

(show top 50) (show all 505)
# Name Status NCT ID Phase Drugs
1 Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent Unknown status NCT00746538 Phase 4
2 Preoperative Biliary Drainage for Resectable Hilar Cholangiocarcinoma Unknown status NCT00797121 Phase 4
3 Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
4 Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Unknown status NCT01256047 Phase 4
5 Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
6 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
7 Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture Unknown status NCT01125865 Phase 4
8 Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Hilar Cholangiocarcinoma Completed NCT00721175 Phase 4
9 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
10 Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4 oral nutritional supplement rich in eicosapentanoic acid
11 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
12 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
13 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
14 Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar Cholangiocarcinoma Unknown status NCT02108145 Phase 2, Phase 3
15 Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma Unknown status NCT02548195 Phase 3 oxaliplatin and gemcitabine;capecitabine
16 Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma Unknown status NCT01739465 Phase 2, Phase 3
17 Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma Unknown status NCT01755013 Phase 2, Phase 3
18 Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures Unknown status NCT00653978 Phase 3
19 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Unknown status NCT02798510 Phase 3 capecitabine;gemcitabine
20 Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma Unknown status NCT01470443 Phase 3 Oxaliplatin;Oxaliplatin
21 Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
22 S-1 and Photodynamic Therapy in Cholangiocarcinoma Completed NCT00869635 Phase 3 S-1 Chemotherapy
23 Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
24 Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery Completed NCT00513539 Phase 3 porfimer sodium
25 Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
26 Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
27 Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
28 Trial of High-dose Urso in Primary Sclerosing Cholangitis Completed NCT00059202 Phase 2, Phase 3 Ursodeoxycholic Acid
29 Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms Completed NCT01640522 Phase 3
30 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
31 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
32 A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302) Recruiting NCT03656536 Phase 3 Pemigatinib;Gemcitabine;Cisplatin
33 Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations Recruiting NCT03773302 Phase 3 BGJ398;Gemcitabine;Cisplatin
34 Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma Recruiting NCT02773485 Phase 3 Systemic chemotherapy
35 SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma Recruiting NCT02807181 Phase 2, Phase 3 Cisplatin-gemcitabine
36 Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma Recruiting NCT03086993 Phase 2, Phase 3 Cisplatin and Gemcitabine
37 A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma Recruiting NCT03251443 Phase 3 Apatinib
38 Bortezomib in Intrahepatic Cholangiocellular Carcinoma Recruiting NCT03345303 Phase 3 Bortezomib
39 HAIC Versus Systemic Chemotherapy for Unresectable ICC Recruiting NCT03771846 Phase 3 gemcitabine, oxaliplatin , fluorouracil, and leucovorin;gemcitabine and oxaliplatin
40 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
41 Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours Recruiting NCT02591030 Phase 2, Phase 3 GEMCIS;mFolfirinox
42 Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection Recruiting NCT03779035 Phase 3 Gemcitabine;Capecitabine
43 Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
44 Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy Recruiting NCT02853474 Phase 3
45 Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L Recruiting NCT02232490 Phase 3
46 Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma Active, not recruiting NCT02482454 Phase 2, Phase 3
47 Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) Active, not recruiting NCT02989857 Phase 3 AG-120;AG-120 matched placebo
48 Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers Active, not recruiting NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
49 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Active, not recruiting NCT02349412 Phase 3
50 Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS) Terminated NCT02082522 Phase 3 Photodynamic therapy-Photofrin;Chemotherapy regimen

Search NIH Clinical Center for Cholangiocarcinoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Cholangiocarcinoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Cholangiocarcinoma:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Cholangiocarcinoma:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 23904171 21498393 22996367 19304471 22555974 15800326 23650429 21325070 24218514 8170938 12242449

Genetic Tests for Cholangiocarcinoma

Genetic tests related to Cholangiocarcinoma:

# Genetic test Affiliating Genes
1 Cholangiocarcinoma, Susceptibility to 30

Anatomical Context for Cholangiocarcinoma

MalaCards organs/tissues related to Cholangiocarcinoma:

42
Liver, Lymph Node, Lung, Small Intestine, Pancreas, Skin, Breast

Publications for Cholangiocarcinoma

Articles related to Cholangiocarcinoma:

(show top 50) (show all 4659)
# Title Authors Year
1
Concurrent Pancreatic Metastasis From Lung Adenocarcinoma and Primary Cholangiocarcinoma on FDG PET/CT Imaging. ( 30762824 )
2019
2
Imaging features of combined hepatocellular and cholangiocarcinoma compared with those of hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in a Chinese population. ( 30799097 )
2019
3
Functional Impairment of Circulating FcεRI+ Monocytes and Myeloid Dendritic Cells in Hepatocellular Carcinoma and Cholangiocarcinoma Patients. ( 30828998 )
2019
4
Imaging of combined hepatocellular-cholangiocarcinoma in cirrhosis and risk of false diagnosis of hepatocellular carcinoma. ( 30788118 )
2019
5
Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma. ( 30690729 )
2019
6
Differentiating between hepatocellular carcinoma and intrahepatic cholangiocarcinoma using contrast-enhanced MRI features: a systematic review and meta-analysis. ( 30704667 )
2019
7
Mouse Model for Hepatocellular Carcinoma and Cholangiocarcinoma Originated from Mature Hepatocytes. ( 30536104 )
2019
8
Analysis of intrahepatic sarcomatoid cholangiocarcinoma: Experience from 11 cases within 17 years. ( 30774275 )
2019
9
Piperlongumine-Eluting Gastrointestinal Stent Using Reactive Oxygen Species-Sensitive Nanofiber Mats for Inhibition of Cholangiocarcinoma Cells. ( 30778693 )
2019
10
GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma. ( 30778887 )
2019
11
Differentiating IgG4-related sclerosing cholangiopathy from cholangiocarcinoma using CT and MRI: experience from a tertiary referring center. ( 30783729 )
2019
12
Enhanced expression of ten-eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P-glycoprotein expression. ( 30784212 )
2019
13
Effectiveness of surgery for recurrent cholangiocarcinoma: A single center experience and brief literature review. ( 30797594 )
2019
14
Preoperative Serum Platelet-Lymphocyte Ratio as a Prognostic Factor in Cholangiocarcinoma Patients after Radical Resection: A Retrospective Analysis of 119 Patients. ( 30809257 )
2019
15
Prognostic factors in patients with advanced extrahepatic cholangiocarcinoma: A single center experience. ( 30813168 )
2019
16
Competing risk analyses of overall survival and cancer-specific survival in patients with combined hepatocellular cholangiocarcinoma after surgery. ( 30813928 )
2019
17
Combined hepatocellular-cholangiocarcinoma: a population level analysis of incidence and mortality trends. ( 30813932 )
2019
18
Intraductal papillary mucinous neoplasm of the biliary tract: A precursor lesion to cholangiocarcinoma. ( 30815047 )
2019
19
YAP and the Hippo pathway in cholangiocarcinoma. ( 30815737 )
2019
20
Association Between Travel Distance, Hospital Volume, and Outcomes Following Resection of Cholangiocarcinoma. ( 30815777 )
2019
21
Molecular Pathogenesis of Cholangiocarcinoma. ( 30819129 )
2019
22
Yttrium-90 Radioembolization Is Cost Effective in Intrahepatic Cholangiocarcinoma: A SEER Medicare Population Study. ( 30819468 )
2019
23
Premalignant lesions of cholangiocarcinoma: characteristics on ultrasonography and MRI. ( 30820627 )
2019
24
Trends in the Incidence, Treatment and Outcomes of Patients with Intrahepatic Cholangiocarcinoma in the USA: Facility Type is Associated with Margin Status, Use of Lymphadenectomy and Overall Survival. ( 30820734 )
2019
25
Intrahepatic Cholangiocarcinoma: Rising Burden and Glaring Disparities. ( 30820787 )
2019
26
Role of Lymph Node Dissection in Small (≤ 3 cm) Intrahepatic Cholangiocarcinoma. ( 30820796 )
2019
27
Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway. ( 30822475 )
2019
28
Induction of cell-cycle arrest and apoptosis in human cholangiocarcinoma cells by pristimerin. ( 30825242 )
2019
29
Surgical and histological boundary of the hepatic hilar plate system: Basic study relevant to surgery for hilar cholangiocarcinoma regarding the "true" proximal ductal margin. ( 30825363 )
2019
30
Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. ( 30825968 )
2019
31
Molecular Perturbations in Cholangiocarcinoma: Is it Time for Precision Medicine? ( 30829432 )
2019
32
Clinical presentation, diagnosis, and staging of cholangiocarcinoma. ( 30831002 )
2019
33
Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases. ( 30832707 )
2019
34
Incretin-based treatment in type 2 diabetes mellitus and risk of cholangiocarcinoma: Is it only adverse drug effect? ( 30833185 )
2019
35
Cholangiocarcinoma and hepatic myelolipoma incarcerated in a peritoneopericardial diaphragmatic hernia with pulmonary metastasis and carcinomatosis in a cat. ( 30834134 )
2019
36
Extensive cavitatory lung metastases in cholangiocarcinoma. ( 30836436 )
2019
37
Impact of Anatomical Versus Non-anatomical Liver Resection on Short- and Long-Term Outcomes for Patients with Intrahepatic Cholangiocarcinoma. ( 30843164 )
2019
38
Diagnostic and prognostic biomarkers in cholangiocarcinoma. ( 30843325 )
2019
39
Surgery For Cholangiocarcinoma. ( 30843343 )
2019
40
Ultrasound-guided percutaneous microwave ablation versus surgical resection for recurrent intrahepatic cholangiocarcinoma: intermediate-term results. ( 30845852 )
2019
41
Cholangiocarcinoma. ( 30846037 )
2019
42
Endoscopic Retrograde Cholangiopancreatography-Guided Ablation for Cholangiocarcinoma. ( 30846158 )
2019
43
Tumor-associated lymphangiogenesis predicts unfavorable prognosis of intrahepatic cholangiocarcinoma. ( 30849953 )
2019
44
High Beclin-1 and ARID1A expression corelates with poor survival and high recurrence in intrahepatic cholangiocarcinoma: a histopathological retrospective study. ( 30849962 )
2019
45
Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma. ( 30850583 )
2019
46
Cholangiocarcinoma: Epidemiology and risk factors. ( 30851228 )
2019
47
Experimental models to unravel the molecular pathogenesis, cell of origin and stem cell properties of cholangiocarcinoma. ( 30851232 )
2019
48
SRC-like adaptor protein negatively regulates Wnt signaling in intrahepatic cholangiocarcinoma. ( 30854048 )
2019
49
High expression of Oct4 and Nanog predict poor prognosis in intrahepatic cholangiocarcinoma patients after curative resection. ( 30854141 )
2019
50
LncRNA MIR22HG inhibits cell proliferation and migration in cholangiocarcinoma through negatively regulating Wnt/β-catenin signaling pathway. ( 30856284 )
2019

Variations for Cholangiocarcinoma

Cosmic variations for Cholangiocarcinoma:

9 (show top 50) (show all 1682)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6974042 ZFHX3 biliary tract,bile duct,carcinoma,NS c.6964C>T p.R2322* 16:72795718-72795718 0
2 COSM6957143 ZFHX3 biliary tract,bile duct,carcinoma,NS c.3529+1G>A p.? 16:72829778-72829778 0
3 COSM6928728 YAP1 biliary tract,bile duct,carcinoma,NS c.434C>G p.T145S 11:102114256-102114256 0
4 COSM6986174 XPO1 biliary tract,bile duct,carcinoma,NS c.273G>T p.W91C 2:61522639-61522639 0
5 COSM6985358 XPO1 biliary tract,bile duct,carcinoma,NS c.338C>T p.T113M 2:61502274-61502274 0
6 COSM6975271 XPO1 biliary tract,bile duct,carcinoma,NS c.729G>T p.E243D 2:61498703-61498703 0
7 COSM6923580 TSC1 biliary tract,bile duct,carcinoma,NS c.2551C>T p.Q851* 9:132900789-132900789 0
8 COSM4172016 TSC1 biliary tract,bile duct,carcinoma,NS c.737+1G>A p.? 9:132921362-132921362 0
9 COSM308173 TRIM28 biliary tract,bile duct,carcinoma,NS c.1475G>T p.R492L 19:58549053-58549053 0
10 COSM44463 TP53 biliary tract,bile duct,carcinoma,NS c.848G>T p.R283L 17:7673772-7673772 0
11 COSM43687 TP53 biliary tract,bile duct,carcinoma,NS c.641A>G p.H214R 17:7674890-7674890 0
12 COSM6932 TP53 biliary tract,bile duct,carcinoma,NS c.733G>A p.G245S 17:7674230-7674230 0
13 COSM43912 TP53 biliary tract,bile duct,carcinoma,NS c.395A>C p.K132T 17:7675217-7675217 0
14 COSM10660 TP53 biliary tract,bile duct,carcinoma,NS c.818G>A p.R273H 17:7673802-7673802 0
15 COSM10662 TP53 biliary tract,bile duct,carcinoma,NS c.743G>A p.R248Q 17:7674220-7674220 0
16 COSM10687 TP53 biliary tract,bile duct,carcinoma,NS c.527G>A p.C176Y 17:7675085-7675085 0
17 COSM10731 TP53 biliary tract,bile duct,carcinoma,NS c.707A>G p.Y236C 17:7674256-7674256 0
18 COSM11073 TP53 biliary tract,bile duct,carcinoma,NS c.1024C>T p.R342* 17:7670685-7670685 0
19 COSM43751 TP53 biliary tract,bile duct,carcinoma,NS c.673-1G>A p.? 17:7674291-7674291 0
20 COSM22908 TP53 biliary tract,bile duct,carcinoma,NS c.376-1G>T p.? 17:7675237-7675237 0
21 COSM44143 TP53 biliary tract,bile duct,carcinoma,NS c.919+1G>A p.? 17:7673700-7673700 0
22 COSM43836 TP53 biliary tract,bile duct,carcinoma,NS c.475G>C p.A159P 17:7675137-7675137 0
23 COSM10742 TP53 biliary tract,bile duct,carcinoma,NS c.578A>G p.H193R 17:7674953-7674953 0
24 COSM1522202 TP53 biliary tract,bile duct,carcinoma,NS c.1051A>T p.K351* 17:7670658-7670658 0
25 COSM44786 TP53 biliary tract,bile duct,carcinoma,NS c.694A>C p.I232L 17:7674269-7674269 0
26 COSM10727 TP53 biliary tract,bile duct,carcinoma,NS c.438G>A p.W146* 17:7675174-7675174 0
27 COSM10648 TP53 biliary tract,bile duct,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 0
28 COSM43596 TP53 biliary tract,bile duct,carcinoma,NS c.841G>A p.D281N 17:7673779-7673779 0
29 COSM43909 TP53 biliary tract,bile duct,carcinoma,NS c.817C>A p.R273S 17:7673803-7673803 0
30 COSM11090 TP53 biliary tract,bile duct,carcinoma,NS c.541C>T p.R181C 17:7675071-7675071 0
31 COSM10690 TP53 biliary tract,bile duct,carcinoma,NS c.473G>A p.R158H 17:7675139-7675139 0
32 COSM6081949 TP53 biliary tract,bile duct,carcinoma,NS c.1060C>T p.Q354* 17:7670649-7670649 0
33 COSM6917440 TP53 biliary tract,bile duct,carcinoma,NS c.736A>C p.M246L 17:7674227-7674227 0
34 COSM10645 TP53 biliary tract,bile duct,carcinoma,NS c.527G>T p.C176F 17:7675085-7675085 0
35 COSM10656 TP53 biliary tract,bile duct,carcinoma,NS c.742C>T p.R248W 17:7674221-7674221 0
36 COSM11071 TP53 biliary tract,bile duct,carcinoma,NS c.1009C>T p.R337C 17:7670700-7670700 0
37 COSM10749 TP53 biliary tract,bile duct,carcinoma,NS c.830G>T p.C277F 17:7673790-7673790 0
38 COSM44151 TP53 biliary tract,bile duct,carcinoma,NS c.535C>A p.H179N 17:7675077-7675077 0
39 COSM44262 TP53 biliary tract,bile duct,carcinoma,NS c.808T>C p.F270L 17:7673812-7673812 0
40 COSM11078 TP53 biliary tract,bile duct,carcinoma,NS c.1027G>T p.E343* 17:7670682-7670682 0
41 COSM10659 TP53 biliary tract,bile duct,carcinoma,NS c.817C>T p.R273C 17:7673803-7673803 0
42 COSM43947 TP53 biliary tract,bile duct,carcinoma,NS c.614A>G p.Y205C 17:7674917-7674917 0
43 COSM10883 TP53 biliary tract,bile duct,carcinoma,NS c.731G>A p.G244D 17:7674232-7674232 0
44 COSM44523 TP53 biliary tract,bile duct,carcinoma,NS c.863A>G p.N288S 17:7673757-7673757 0
45 COSM10672 TP53 biliary tract,bile duct,carcinoma,NS c.577C>T p.H193Y 17:7674954-7674954 0
46 COSM10725 TP53 biliary tract,bile duct,carcinoma,NS c.701A>G p.Y234C 17:7674262-7674262 0
47 COSM43850 TP53 biliary tract,bile duct,carcinoma,NS c.659A>C p.Y220S 17:7674872-7674872 0
48 COSM10771 TP53 biliary tract,bile duct,carcinoma,NS c.749C>T p.P250L 17:7674214-7674214 0
49 COSM69404 TP53 biliary tract,bile duct,carcinoma,NS c.994-1G>A p.? 17:7670716-7670716 0
50 COSM10893 TP53 biliary tract,bile duct,carcinoma,NS c.824G>A p.C275Y 17:7673796-7673796 0

Copy number variations for Cholangiocarcinoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 111150 17 35097918 35138441 Copy number ERBB2 Cholangiocarcinoma
2 118016 17 7512444 7519279 Copy number P53 Cholangiocarcinoma
3 159441 21 42600000 48129895 Amplification TFF1 Cholangiocarcinoma
4 159442 21 42600000 48129895 Amplification TFF2 Cholangiocarcinoma
5 159443 21 42600000 48129895 Amplification TFF3 Cholangiocarcinoma

Expression for Cholangiocarcinoma

Search GEO for disease gene expression data for Cholangiocarcinoma.

Pathways for Cholangiocarcinoma

Pathways related to Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.5 MIR141 MIR152 MIR200B MIR21 MIR373
2 10.59 MIR141 MIR200B

GO Terms for Cholangiocarcinoma

Cellular components related to Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 MIR141 MIR148A MIR152 MIR204 MIR21 MIR320A
2 micro-ribonucleoprotein complex GO:0035068 9.32 H19 MIR141 MIR148A MIR152 MIR200B MIR204

Biological processes related to Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 miRNA mediated inhibition of translation GO:0035278 9.33 MIR148A MIR204 MIR21
2 gene silencing by miRNA GO:0035195 9.32 H19 MIR141 MIR148A MIR152 MIR200B MIR204
3 negative regulation of blood vessel endothelial cell migration GO:0043537 9.13 MIR152 MIR200B MIR204

Molecular functions related to Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.17 MIR141 MIR148A MIR152 MIR200B MIR204 MIR21

Sources for Cholangiocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....